Assessing Risk of Myelosuppression With PARP Inhibitors in Prostate Cancer With Karan Jatwani, MBBS
Expert Perspectives · Keira Smith · 2024-06-14
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Karan Jatwani, third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, sat down to discuss his poster on “Risk Assessment of Myelosuppression with PARP Inhibitors in Prostate Cancer: Insights from FAERS.” This is the first study analyzing the relative rates of myelosuppression events across poly-ADP ribose polymerase (PARP) inhibitors specifically in prostate cancer. In this conversation with Dr. Salman Faisal, Dr. Jatwani elaborates on the research, including:
- Background about the four PARP inhibitors approved for metastatic castration-resistant prostate cancer (CRPC)—olaparib, niraparib, rucaparib, and talazoparib—and their risks of myelosuppressive events
- His team’s study investigating pharmacovigilance, reporting rate, and reaction outcomes of approved PARP inhibitors for metastatic CRPC in US Food and Drug Administration Adverse Event Reporting System (FAERS)
- The incidence of myelosuppressive events, including anemia, leukopenia, thrombocytopenia, pancytopenia, myelodysplastic syndrome, and acute myeloid leukemia, that was found
- Implications for patient selection and vigilant monitoring required to optimize the safety and efficacy of PARP inhibitors in prostate cancer
- And more!
About Dr. Jatwani
Karan Jatwani, MBBS, is a third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York. His research centers around genitourinary cancers, with a focus on patient outcomes, health disparities, and novel therapeutics.